Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81936 | 0.86 | DRD2 (0.55) | DRD2SLC18A3KDM1ACARM1PRMT6 | |
| SCHEMBL14320360 | 0.84 | DRD2 (0.54) | DRD2SLC18A3KDM1ACARM1PRMT6 | |
| SCHEMBL8096432 | 0.84 | DRD2 (0.68) | DRD2SLC18A3KDM1ACARM1PRMT6 | |
| SCHEMBL25269977 | 0.84 | KDM4E (0.54) | DRD2KDM4E | |
| SCHEMBL31223124 | 0.82 | DRD2 (0.73) | DRD2SLC18A3 | |
| SCHEMBL4576853 | 0.81 | DRD2 (0.50) | DRD2SLC18A3KDM1ACARM1PRMT6 | |
| SCHEMBL22804730 | 0.81 | DRD2 (0.50) | DRD2SLC18A3KDM1ACARM1PRMT6 | |
| SCHEMBL1305330 | 0.80 | SLC18A3 (0.58) | DRD2SLC18A3KDM1A | |
| SCHEMBL14862765 | 0.79 | KDM4E (0.51) | KDM4ERECQLTDP1KDM1ACARM1 | |
| SCHEMBL22804710 | 0.79 | DRD2 (0.50) | DRD2SLC18A3PRCPCARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552801-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4522617-A1 | NEW INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| CN-119173518-A | Indazole derivatives | 豪夫迈·罗氏有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-113993872-B | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20240059692-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-02-22 | — | — | US | disclosed |
| WO-2023217923-A1 | NEW INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-11-16 | — | — | WO | disclosed |
| CN-116507328-A | Indazole derivatives | 豪夫迈·罗氏有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-3986896-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993872-A | EGFR inhibitors for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020254572-A1 | EGFR INHIBITORS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059692-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, ABCB11, CYP3A7 | DRD2 1294/4885SLC18A3 1710/4885KDM4E 2655/4885 |
| US-12552801-B2 | Indazole derivatives | EGFR, ABL1, ERBB3 | DRD2 667/4885SLC18A3 2158/4885KDM4E 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.